Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review.
The insulin analogs lispro, aspart, and glulisine are the only commercially available rapid-acting insulins to treat diabetes. We review the evidence for treating hyperglycemia, using insulin, and specifically using rapid-acting analogs in diabetic individuals, on the prevention of vascular events. We review the beneficial effects of insulin on the vascular system, which include vasodilation and anti-inflammatory actions. The effects of treating hyperglycemia and intensive blood glucose control on vascular outcomes are reviewed.
Department of Medicine, Division of Endocrinology, University of Texas, Southwestern Medical Center, Dallas, TX 75390-8858, USA.
Steve
S
Fordan
Philip
P
Raskin
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000187:drug effects; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000209:etiology / Q000517:prevention & control*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D061267:Insulin Aspart; D061268:Insulin Lispro; D019518:Postprandial Period; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D061267:Insulin Aspart; D061268:Insulin Lispro; D014665:Vasodilator Agents; C517652:hemoglobin A1c protein, human; C479079:insulin glulisine